Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.52 |
| ▸ | PLAT | P00750 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL239345 | 0.99 | HTR2C (0.54) | HTR2CPLATCYP1A2CYP2C19SLC6A2 | |
| SCHEMBL3941345 | 0.75 | HPGDS (0.50) | HTR2CPLATHTR2A | |
| SCHEMBL2755237 | 0.75 | HTR2C (0.54) | HTR2CPLAT | |
| Hydrochloric Acid SCHEMBL237629 | 0.74 | HTR2C (0.55) | HTR2CPLATSLC6A2HTR1ASLC6A3 | |
| SCHEMBL2755235 | 0.74 | MEN1 (0.56) | HTR2CPLATCYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL238482 | 0.73 | HTR2C (0.56) | HTR2CPLATCYP1A2CYP2C9 | |
| SCHEMBL2755245 | 0.71 | PLAT (0.42) | HTR2CPLAT | |
| Tert-Butyl Formate SCHEMBL27752005 | 0.71 | HPGDS (0.39) | HTR2CPLATHTR2A | |
| SCHEMBL238932 | 0.70 | PLAT (0.43) | PLATCYP1A2SLC6A2SLC6A4HTR1A | |
| SCHEMBL31429068 | 0.70 | HSD11B1 (0.45) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | HTR2C 4004/4885PLAT 1906/4885CYP1A2 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.